TRMT12: A Potential Drug Target and Biomarker for ALS (G55039)

Target Name: TRMT12

NCBI ID: G55039

TRMT12

TRMT12: A Potential Drug Target and Biomarker for ALS

Transtage RNA methyltransferase 12 (TRMT12) is a non-coding RNA molecule that is expressed in various tissues and cell types in the human body. It is a key player in the regulation of gene expression and has been implicated in a number of biological processes, including aging, neurodegenerative diseases, and cancer. In recent years, researchers have identified TRMT12 as a potential drug target and biomarker for a variety of diseases, including Alzheimer's disease (ALS).

ALS is a progressive neurodegenerative disease that is characterized by the progressive loss of nerve cells in the brain. It is the most common adult-onset neurodegenerative disease and its prevalence is expected to reach 13.8 million Americans by 2030. The underlying causes of ALS are not fully understood, but research has identified genetic and environmental factors that contribute to its development.

TRMT12 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression in various cell types. It is expressed in the brain and has been shown to be involved in the regulation of protein synthesis, cellular signaling, and stress response.

Recent studies have identified TRMT12 as a potential drug target for ALS. Researchers have found that TRMT12 is overexpressed in the brains of people with ALS and that inhibiting its activity could potentially be a therapeutic approach for the disease. In fact, several studies have shown that TRMT12 inhibitors have been effective in animal models of ALS, leading to the hope that they could be effective in humans as well.

In addition to its potential as a drug target, TRMT12 has also been identified as a potential biomarker for ALS. The loss of cellular stress response proteins, including TRMT12, has been shown to contribute to the development of neurodegenerative diseases. Therefore, measuring the levels of TRMT12 in brain tissue could potentially be a diagnostic tool for ALS.

TRMT12 is also a potential target for other neurodegenerative diseases, including Parkinson's disease and Huntington's disease. In fact, recent studies have shown that TRMT12 is overexpressed in the brains of people with Parkinson's disease and that inhibiting its activity could potentially be a therapeutic approach for the disease.

In conclusion, TRMT12 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been implicated in a number of biological processes, including aging, neurodegenerative diseases, and cancer. Its potential as a drug target and biomarker for ALS makes it an important area of research and a potential treatment for these debilitating diseases. Further studies are needed to fully understand the role of TRMT12 in the development and progression of ALS and other neurodegenerative diseases.

Protein Name: TRNA Methyltransferase 12 Homolog

Functions: S-adenosyl-L-methionine-dependent transferase that acts as a component of the wybutosine biosynthesis pathway. Wybutosine is a hyper modified guanosine with a tricyclic base found at the 3'-position adjacent to the anticodon of eukaryotic phenylalanine tRNA. Catalyzes the transfer of the alpha-amino-alpha-carboxypropyl (acp) group from S-adenosyl-L-methionine to the C-7 position of 4-demethylwyosine (imG-14) to produce wybutosine-86

The "TRMT12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRMT12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets